Samsung Biologics partners on antibody development, manufacturing

By The Science Advisory Board staff writers

November 2, 2020 -- Samsung Biologics has announced that its contract development and manufacturing organization (CDMO) services have been selected by two companies for their antibody candidates.

Samsung Biologics and Checkpoint Therapeutics have expanded their long-term manufacturing partnership for Checkpoint's anti-programmed cell death ligand 1 (PD-L1) antibody, cosibelimab. The agreement builds on an existing agreement in 2017. Now, Samsung Biologics will provide additional commercial-scale drug substance manufacturing for Checkpoint. Samsung will begin manufacturing in 2021.

Cosibelimab is currently under clinical investigation for the treatment of metastatic cutaneous squamous cell carcinoma. Checkpoint anticipates reporting results from the trial in mid-2021.

Samsung Biologics has also entered into a new strategic partnership with GeneQuantum Healthcare in China for the joint development of an antibody drug conjugate (ADC) for the treatment of non-small cell lung carcinoma, triple-negative breast cancer, and other solid tumors. GeneQuantum has chosen Samsung Biologics as its CDMO partner for its second antibody candidate.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here